

=&gt; d ibib abs hitind 1-6

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 2011:371584 CAPLUS <<LOGINID::20110605>>  
 DOCUMENT NUMBER: 154:394818  
 TITLE: A solid formulation and the preparation method thereof  
 INVENTOR(S): Zhong, Shuguang  
 PATENT ASSIGNEE(S): Peop. Rep. China  
 SOURCE: Faming Zhuanli Shenqing, 28pp.  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101987082	A	20110323	CN 2010-10228318	20100716
PRIORITY APPLN. INFO.:			CN 2010-10228318	20100716

AB Title solid formulation has high wet-stability and good mech. property, and it is composed of wet-unstable material, sugar alc. (I) without hygroscopic property at room temperature, hydrophilic melt adhesives without hygroscopic property at room temperature and with m.p. lower than that of sugar alc. (I), and/or pharmaceutically acceptable addition agent, and/or a active component. The sugar alc. (I) is selected from erythrose, mannitol, isomaltitol monomer 1,6-GPS, isomaltitol monomer 1,6-GPM, and their mixture. The melt adhesive is selected from PEG with m.p. lower than that of sugar alc. (I) and active component and without hygroscopic property at 10<sup>°</sup>, and or sugar alc. (II) with m.p. lower than that of sugar alc. (I) and active component and without hygroscopic property at 10<sup>°</sup>. The mol. weight of PEG is 6000-20,000. Sugar alc. (II) is erythrose. Wet-unstable material comprises wet-unstable antidepressant,  $\beta$ -receptor antagonist, antidiabetic, analgesics, anti-inflammatory medicine etc. The solid formulation comprises tablet, capsule, granule, peppermint, ingot, microcapsule, instant solid formulation, suppository, film, pill, sustained-release or controlled-release formulation. The preparation method comprises forming bridging material from sugar alc. (I) without hygroscopic property at room temperature, hydrophilic melt adhesives without hygroscopic property at room temperature and with m.p. lower than that of sugar alc. (I) to isolating internal environment and exotic environment.

IPCI A61K0009-00 [I,A]; A61K0047-02 [I,A]; A61K0047-04 [I,A]; A61K0047-10 [I,A]; A61K0047-12 [I,A]; A61K0047-16 [I,A]; A61K0047-20 [I,A]; A61K0047-22 [I,A]; A61K0047-26 [I,A]; A61K0047-32 [I,A]; A61K0047-34 [I,A]; A61K0047-36 [I,A]; A61K0047-38 [I,A]; A61K0047-40 [I,A]; A61K0047-42 [I,A]

CC 63-6 (Pharmaceuticals)

IT 50-07-7 50-18-0, Cyclophosphamide 50-21-5, Lactic acid, biological studies 50-34-0, Propantheline bromide 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-55-5, Reserpine 50-70-4, Sorbitol, biological studies 50-78-2 50-81-7, Vitamin C, biological studies 50-99-7, D-Glucose, biological studies 51-21-8, Fluorouracil 51-34-3, Scopolamine 51-43-4, Adrenaline 51-61-6, Dopamine, biological studies 51-67-2, Tyramine 52-01-7, Spironolactone 52-24-4, Thiotepa 52-28-8, Codeine phosphate 52-53-9, Verapamil 52-86-8, Haloperidol 52-90-4, L-Cysteine, biological studies 53-86-1, Indomethacin 54-31-9, Furosemide 55-56-1, Chlorhexidine 55-65-2, Guanethidine 56-84-8, L-Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological

studies 57-22-7, Vincristine 57-27-2, Morphine, biological studies  
 57-41-0, Phenytoin 57-42-1, Pethidine 57-48-7, Fructose, biological  
 studies 57-50-1, Sucrose, biological studies 57-63-6,  
 Ethinyloestradiol 57-92-1, Streptomycin 58-08-2, Caffeine, biological  
 studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-39-9,  
 Perphenazine 58-55-9, Theophylline, biological studies 58-93-5,  
 Hydrochlorothiazide 59-05-2, Methotrexate 59-26-7, Nikethamide  
 59-46-1, Procaine 59-92-7, Levodopa, biological studies 59-98-3,  
 Tolazoline 59-99-4, Neostigmine 60-54-8, Tetracycline 60-56-0,  
 Methimazole 60-80-0, Antipyrine 61-33-6, biological studies 61-56-3,  
 Sultiam 61-68-7, Mefenamic acid 63-42-3, Lactose 64-77-7,  
 Tolbutamide 65-85-0, Benzoic acid, biological studies 67-03-8,  
 Thiamine hydrochloride 67-52-7, Barbituric acid 68-04-2, Sodium  
 citrate 68-88-2, Hydroxyzine 68-89-3, Analgin 69-09-0,  
 Chlorpromazine hydrochloride 69-65-8, Mannitol 69-72-7D, derivs.  
 69-79-4, Maltose 70-00-8, Trifluridine 70-18-8, Glutathione,  
 biological studies 71-27-2, Suxamethonium chloride 76-57-3, Codeine  
 76-99-3, Methadone 77-67-8, Ethosuximide 77-92-9, Citric acid,  
 biological studies 79-09-4, Propionic acid, biological studies  
 79-14-1, Glycolic acid, biological studies 81-81-2, Warfarin 83-43-2,  
 Methylprednisolone 83-67-0, Theobromine 84-22-0, Tetrahydrozoline  
 84-55-9, Viqual 86-21-5, Pheniramine 86-54-4, Hydralazine 87-69-4,  
 Tartaric acid, biological studies 89-57-6, Mesalazine 91-64-5,  
 Coumarin 91-81-6, Tripeleminamine 92-84-2, Phenothiazine 99-20-7,  
 Mycose 99-66-1, Valproic acid 101-26-8, Pyridostigmine bromide  
 103-90-2, p-Acetamidophenol 107-35-7, Taurine 110-15-6, Succinic acid,  
 biological studies 110-16-7, Maleic acid, biological studies 110-17-8,  
 Fumaric acid, biological studies 113-45-1, Methylphenidate 118-71-8,  
 Maltol 124-04-9, Adipic acid, biological studies 124-94-7,  
 Triamcinolone 125-58-6, Levomethadone 128-13-2, Ursodesoxycholic acid  
 128-62-1, Narcotine 129-51-1, Ergometrine maleate 137-08-6, Calcium  
 pantothenate 147-94-4, Cytarabine 153-18-4, Rutin 154-42-7,  
 Thioguanine 155-09-9, Tranlycypromine 297-90-5, Methorphan  
 298-46-4, Carbamazepine 299-42-3, Ephedrine 315-30-0, Allopurinol  
 321-64-2, Tacrine 357-70-0, Galantamine 359-83-1, Pentazocine  
 364-62-5, Metoclopramide 396-01-0, Triamterene 437-38-7, Fentanyl  
 437-74-1, Xanthinol nicotinate 439-14-5, Diazepam 440-17-5,  
 Trifluoperazine hydrochloride 443-48-1, Metronidazole 446-86-6,  
 Azathioprine 465-65-6, Naloxone 472-11-7, Ruscogenin 474-25-9,  
 Chenodeoxycholic acid 479-18-5, Diprophylline 479-92-5, Propyphenazone  
 484-23-1, Dihydralazine 486-12-4, Triprolidine 523-87-5,  
 Dimenhydrinate 525-66-6, Propranolol 557-04-0, Magnesium stearate  
 569-65-3, Meclozine 577-11-7, Docusate sodium 599-79-1, Sulfasalazine  
 614-39-1, Procainamide hydrochloride 638-94-8, Desonide 657-24-9,  
 Metformin 728-88-1, Tolperisone 738-70-5, Trimethoprim 739-71-9,  
 Trimipramine 745-65-3, Alprostadil 749-13-3, Trifluoperidol 768-94-5,  
 Amantadine 846-50-4, Temazepam 865-21-4, Vinblastine 1028-33-7,  
 Pentifylline 1070-11-7, Ethambutol hydrochloride 1077-28-7, Thiocetic  
 acid 1082-57-1, Tramazoline 1172-18-5, Flurazepam hydrochloride  
 1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1400-61-9,  
 Nystatin 1402-38-6, Actinomycin 1403-66-3, Gentamicin 1404-88-2,  
 Tyrothricin 1404-90-6, Vancomycin 1405-10-3, Neomycin sulphate  
 1406-16-2, Vitamin D 1491-59-4, Oxymetazoline 1617-90-9, Vincamine  
 1642-54-2, Diethylcarbamazine citrate 1695-77-8, Spectinomycin  
 1744-22-5, Riluzole 1758-51-6, Erythrose 2098-66-0, Cyproterone  
 2398-96-1, Tolnaftate 2410-93-7, Methopterin 2438-72-4, Bufexamac  
 3056-17-5, Stavudine 3416-24-8, Glucosamine 3605-01-4, Piribedil  
 3625-06-7, Mebeverine 3734-33-6, Denatonium benzoate 3778-73-2,  
 Ifosfamide 3930-20-9, Sotalol 4070-80-8 4205-90-7, Clonidine

4394-00-7, Niflumic acid 4419-39-0, Beclomethasone 4910-46-7, Spaglumic acid 4969-02-2, Metixene 4991-65-5, Thioxolone 5536-17-4, Vidarabine 6284-40-8, Meglumine 6493-05-6, Pentoxifylline 6506-37-2, Nimorazole 6990-06-3, Fusidic acid 7085-55-4, Troxerutin 7447-40-7, Potassium chloride, biological studies 7481-89-2, Zalcitabine 7491-74-9, Piracetam 7631-86-9, Silicon dioxide, biological studies 7632-04-4, Sodium perborate 7647-14-5, Sodium chloride, biological studies 7681-93-8, Natamycin 7683-59-2, Isoprenaline 7778-54-3, Calcium hypochlorite 8025-81-8, Spiramycin 9000-01-5, Arabic gum 9000-07-1, Carrageenan 9000-30-0, Guar gum 9002-07-7, Trypsin 9002-68-0, Follitropin 9002-89-5, Polyvinyl alcohol 9003-39-8, Povidone 9004-32-4, Sodium carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-53-9, Dextrin 9004-54-0, Dextran, biological studies 9004-61-9, Hyaluronic acid 9004-81-3, Polyoxyethylene laurate 9004-99-3 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-49-6, Heparin, biological studies 9007-92-5, Glucagon, biological studies 9012-76-4, Chitosan 9063-38-1, Sodium carboxymethyl starch 10117-38-1, Potassium sulfite 10118-90-8, Minocycline 10238-21-8, Glibenclamide 10262-69-8, Maprotiline 10540-29-1, Tamoxifen 11041-12-6, Cholestyramine 11096-26-7, Epoetin 11111-12-9, Cephalosporin 12174-11-7, Attapulgate 12619-70-4, Cyclodextrin 12794-10-4, Benzodiazepine 13010-47-4, Lomustine 13073-96-6 13292-46-1, Rifampicin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(solid formulation and preparation method thereof)

IT 13311-84-7, Flutamide 13523-86-9, Pindolol 13870-90-1, Cobamamide 14222-60-7, Protionamide 14293-44-8, Xipamide 14636-12-5, Terlipressin 14860-49-2, Clobutinol 15307-86-5, Diclofenac 15421-84-8, Trapidil 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16110-51-3, Cromolyn 16662-47-8, Gallopamil 16731-55-8, Potassium pyrosulfite 17194-00-2, Barium hydroxide 17692-38-5, Fluprofen 18016-80-3, Lisuride 18323-44-9, Clindamycin 18559-94-9, Salbutamol 18683-91-5, Ambroxol 18996-35-5, Sodium dihydrogen citrate 19216-56-9, Prazosin 19387-91-8, Tinidazole 19388-87-5, Taurolidine 19794-93-5, Trazodone 20594-83-6, Nalbuphine 21645-51-2, Aluminum hydroxide, biological studies 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22089-22-1, Trofosfamide 22204-53-1, Naproxen 22839-47-0, Aspartame 22916-47-8, Miconazole 23031-25-6, Terbutaline 23047-25-8, Lofepamine 23155-02-4, Fosfomycin 23694-81-7, Mepindolol 24219-97-4, Mianserine 25087-26-7, Polymethacrylic acid 25316-40-9, Adriamycin 25322-68-3, Polyethylene glycol 25812-30-0, Gemfibrozil 26446-38-8, Sucrose palmitate 26615-21-4, Zotepine 26839-75-8, Timolol 26844-12-2, Indoramine 27203-92-5, Tramadol 27220-47-9, Econazole 27523-40-6, Isoconazole 27574-24-9, Tropatepine 27848-84-6, Nicergoline 28088-64-4, Aminosalicic acid 28231-58-5, L-Lysine carbonate 28797-61-7, Pirenzepine 29122-68-7, Atenolol 29767-20-2, Teniposide 30516-87-1, Zidovudine 30544-47-9, Etofenamate 31431-39-7, Mebendazole 31637-97-5, Etofibrate 33419-42-0, Etoposide 33996-33-7, Oxaceprol 34580-13-7, Ketotifen 34661-75-1, Urapidil 36322-90-4, Piroxicam 36791-04-5, Ribavirin 37318-31-3, Sucrose stearate 38304-91-5, Minoxidil 39809-25-1, Penciclovir 41570-61-0, Tulobuterol 41859-67-0 42399-41-7, Diltiazem 42471-28-3, Nimustine 42971-09-5, Vinpocetine 46817-91-8, Viloxazine 49562-28-9, Fenofibrate 50679-08-8, Terfenadine 50700-72-6, Vecuronium 51012-32-9, Tiapride 51322-75-9, Tizanidine 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetine 51931-66-9, Tilidine 52468-60-7, Flunarizine 52485-79-7, Buprenorphine 53179-11-6, Loperamide 53230-10-7, Mefloquine 53643-48-4, Vindesine 53783-83-8, Tromantadine 54063-54-6, Reproterol 54182-58-0, Sucralfate

54182-62-6, Polacrillin potassium 54910-89-3, Fluoxetine 55142-85-3,  
 Ticlopidine 55837-29-1, Tiopramide 56030-54-7, Sufentanil  
 56038-13-2, Sucralose 56180-94-0, Acarbose 56211-40-6, Torasemide  
 57460-41-0, Talinolol 57576-44-0, Aclarubicin 57808-66-9, Domperidone  
 58001-44-8, Clavulanic acid 58957-92-9, Idarubicin 59122-46-2,  
 Misoprostol 59277-89-3, Acyclovir 59804-37-4, Tenoxicam 59865-13-3,  
 Cyclosporin 60569-19-9, Propiverine 61869-08-7, Paroxetine  
 62571-86-2, Captopril 63590-64-7, Terazosin 63675-72-9, Nisoldipine  
 64211-45-6, Oxiconazole 65277-42-1, Ketoconazole 65807-02-5, Goserelin  
 65899-73-2, Tioconazole 66085-59-4, Nimodipine 66357-35-5, Ranitidine  
 68373-14-8, Sulbactam 68506-86-5, Vigabatrin 68693-11-8, Modafinil  
 69756-53-2, Halofantrine 70458-96-7, Norfloxacin 71125-38-7, Meloxicam  
 71486-22-1, Vinorelbine 72479-26-6, Fenticonazole 72509-76-3,  
 Felodipine 73573-87-2, Formoterol 73590-58-6, Omeprazole 74191-85-8,  
 Doxazosin 74512-12-2, Omoconazole 75847-73-3, Enalapril 76547-98-3,  
 Lisinopril 76824-35-6, Famotidine 78273-80-0, Roxatidine 79617-96-2,  
 Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin  
 80214-83-1, Roxithromycin 80573-04-2, Balsalazide 80863-62-3, Alitame  
 81093-37-0, Pravastatin 81103-11-9, Clarithromycin 82410-32-0,  
 Ganciclovir 82419-36-1, Ofloxacin 82626-48-0, Zolpidem 82768-85-2,  
 Quinaprilat 83647-97-6, Spirapril 83688-84-0, Tertatolol 83881-51-0,  
 Cetirizine 83905-01-5, Azithromycin 84625-61-6, Itraconazole  
 85441-61-8, Quinapril 87333-19-5, Ramipril 87679-37-6, Trandolapril  
 88150-42-9, Amlodipine 89365-50-4, Salmeterol 90357-06-5, Bicalutamide  
 91161-71-6, Terbinafine 91374-21-9, Ropinirole 93413-69-5, Venlafaxine  
 93957-54-1, Fluvastatin 96036-03-2, Meropenem 96829-58-2, Orlistat  
 97240-79-4, Topiramate 97682-44-5, Irinotecan 97867-33-9,  
 Ciprofloxacin lactate 99592-32-2, Sertaconazole 99614-02-5,  
 Ondansetron 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole  
 103628-46-2, Sumatriptan 103775-10-6, Moexipril 103890-78-4,  
 Lacidipine 104227-87-4, Famciclovir 104632-26-0, Pramipexole  
 104987-11-3, Tacrolimus 105462-24-6, Risedronate 106392-12-5,  
 Poloxamer 106516-24-9, Sertindole 107753-78-6, Zafirlukast  
 108612-45-9, Mizolastine 110871-86-8, Sparfloxacin 111974-69-7,  
 Quetiapine 115103-54-3, Tiagabine 118292-40-3, Tazarotene  
 119141-88-7, Esomeprazole 120014-06-4, Donepezil 120511-73-1,  
 Anastrozole 122320-73-4, Rosiglitazone 124832-26-4, Valaciclovir  
 125602-71-3, Bepotastine 132539-06-1, Olanzapine 134308-13-7,  
 Tolcapone 134523-00-5, Atorvastatin 139264-17-8, Zolmitriptan  
 139481-59-7, Candesartan 145158-71-0, Tegaserod 155213-67-5, Ritonavir  
 169590-42-5, Celecoxib 181695-72-7, Valdecoxib 196618-13-0,  
 Oseltamivir 791102-93-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (solid formulation and preparation method thereof)

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:1569696 CAPLUS <<LOGINID::20110605>>

DOCUMENT NUMBER: 154:55988

TITLE: Co-administration of an agent linked to an  
 internalization peptide with an anti-inflammatory

INVENTOR(S): Tymianksi, Michael; Garman, Jonathan David; Cui, Hong

PATENT ASSIGNEE(S): Nono, Inc., Can.; Arbor Vita Corporation

SOURCE: PCT Int. Appl., 94pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010144742	A2	20101216	WO 2010-US38226	20100610
WO 2010144742	A3	20110421		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2009-185943P P 20090610

AB The invention provides methods of delivering pharmacol. agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar mol. Such methods are premised in part on the results described in the examples whereby administration of a pharmacol. agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension. The invention provides a method of inhibiting cerebral ischemia due to endovascular surgery, comprising: administering to a subject undergoing endovascular surgery a pharmacol. agent that inhibits binding of PSD95 to NMDAR 2B linked to an internalization peptide in a regime effective to inhibit cerebral ischemia; and administering to the subject a mast cell degranulation inhibitor, where by the mast cell degranulation inhibitor can inhibit an anti-inflammatory response inducible by the internalization peptide and/or the mast cell degranulation inhibitor is administered within a period of 30 min before to 15 min after the pharmacol. agent.

IPCI A61K0038-16 [I,A]; A61K0038-10 [I,A]; A61K0038-08 [I,A]; A61K0031-275 [I,A]; A61P0029-00 [I,A]; A61P0009-00 [I,A]; A61K0038-16 [I,A]; A61K0031-275 [I,A]; A61K0038-08 [I,A]; A61K0038-10 [I,A]; A61P0009-00 [I,A]; A61P0029-00 [I,A]

IPCR A61K0038-16 [I,A]; A61K0031-275 [I,A]; A61K0038-08 [I,A]; A61K0038-10 [I,A]; A61P0009-00 [I,A]; A61P0029-00 [I,A]

CC 1-7 (Pharmacology)

Section cross-reference(s): 63

IT 50-02-2, Dexamethasone 58-73-1, Diphenhydramine 91-84-9, Pyrilamine 95-25-0, Chlorzoxazone 147-24-0, Benadryl 7683-59-2, Isoproterenol 16110-51-3, Cromolyn 38677-81-5, Pirbuterol 53882-12-5, Lodoxamide 53902-12-8, Tranilast 58581-89-8, Azelastine 66357-35-5, Ranitidine 69372-19-6, Pemirolast 80012-43-7, Epinastine 113806-05-6, Olopatadine 125602-71-3, Bepotastine 137071-32-0, Pimecrolimus

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration of agents such as PSD95-NMDAR2B interaction inhibitors linked to internalization peptide with antiinflammatory agent to prevent inflammatory response in treating cerebral ischemia)

IT 7647-14-5, Sodium chloride, biological studies 7732-18-5, Water, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(formulation with; coadministration of agents such as PSD95-NMDAR2B

interaction inhibitors linked to internalization peptide with  
antiinflammatory agent to prevent inflammatory response in treating  
cerebral ischemia)

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:1260515 CAPLUS <<LOGINID::20110605>>

DOCUMENT NUMBER: 151:433913

TITLE: Use of an inhibitor of TNF $\alpha$  plus an  
antihistamine to treat allergic rhinitis and allergic  
conjunctivitis

INVENTOR(S): Yanni, John M.; Gamache, Daniel A.; Miller, Steven T.;  
Beauregard, Clay

PATENT ASSIGNEE(S): Alcon Research, Ltd., USA

SOURCE: PCT Int. Appl., 19pp.; Chemical Indexing Equivalent to  
149:478681 (US)  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009126682	A2	20091015	WO 2009-US39859	20090408
WO 2009126682	A3	20091210		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20080254029	A1	20081016	US 2008-100715	20080410
US 20090182035	A1	20090716	US 2009-406755	20090318
PRIORITY APPLN. INFO.:			US 2008-100715	A 20080410
			US 2009-406755	A 20090318
			US 2007-911176P	P 20070411

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed are methods of treating allergic conjunctivitis and allergic rhinitis in a subject that involve topically administering to the subject a composition comprising a pharmaceutically effective amount of an H1 antagonist

and an anti-TNF $\alpha$  compound Thus, topical ophthalmic composition comprised (in wt%): emedastine 0.05, etanercept 5.0, dibasic sodium phosphate or tromethamine 0.01-0.5, sodium chloride 0.1-0.8, mannitol or sucrose 1-5, polysorbate 80 0.01-0.5, NaOH and/or HCl to pH 7  $\pm$  2, polyquad 0-0.005, purified water q.s. 100.

IPCI A61K0045-06 [I,A]; A61P0011-02 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0031-275 [I,C]; A61K0031-275 [I,A]; A61K0031-335 [I,C]; A61K0031-335 [I,A]; A61P0011-00 [I,C]; A61P0011-02 [I,A]; A61P0027-00 [I,C]; A61P0027-14 [I,A]

IPCR A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61K0009-00 [I,C]; A61K0009-00 [I,A]; A61K0031-275 [I,C]; A61K0031-275 [I,A]; A61K0031-335 [I,C]; A61K0031-335 [I,A]; A61P0011-00 [I,C]; A61P0011-02 [I,A]; A61P0027-00

[I,C]; A61P0027-14 [I,A]  
 CC 63-6 (Pharmaceuticals)  
 IT 57-50-1, Sucrose, biological studies 57-55-6, Propylene Glycol, biological studies 69-65-8, Mannitol 77-86-1, Tromethamine 94-13-3, Propyl Paraben 99-76-3, Methyl Paraben 112-92-5, Stearyl Alcohol 151-21-3, Sodium Lauryl Sulfate, biological studies 5636-83-9, Dimetindene 7558-79-4, Dibasic Sodium Phosphate 7647-14-5, Sodium Chloride, biological studies 9005-65-6, Polysorbate 80 36653-82-4, Cetyl Alcohol 58581-89-8, Azelastine 75345-27-6, Polyquad 79516-68-0, Levocabastine 80012-43-7, Epinastine 83881-51-0, Cetirizine 87233-61-2, Emedastine 100643-71-8, Desloratadine 104987-11-3, Tacrolimus 108612-45-9, Mizolastine 113806-05-6, Olopatadine 125602-71-3, Bepotastine 130018-77-8, Levocetirizine 133550-30-8, AG490 170277-31-3, Infliximab 185243-69-0, Etanercept 202475-60-3, WHI-P131 205598-06-7, PNU156804 211555-04-3, WHIP-154 211555-05-4, WHIP-97 331731-18-1, Adalimumab 477600-75-2, CP-690550 911825-19-9 911825-20-2 1070655-77-4 1070655-78-5 1070655-79-6 1070894-00-6, PS 608504  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibitor of TNF $\alpha$  plus antihistamine use to treat allergic rhinitis and allergic conjunctivitis)  
 OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
 (3 CITINGS)

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 2008:1251822 CAPLUS <<LOGINID::20110605>>  
 DOCUMENT NUMBER: 149:478681  
 TITLE: Use of an inhibitor of TNF $\alpha$  plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis  
 INVENTOR(S): Yanni, John M.; Gamache, Daniel A.; Miller, Steven T.; Beauregard, Clay  
 PATENT ASSIGNEE(S): Alcon Research, Ltd., USA  
 SOURCE: U.S. Pat. Appl. Publ., 9pp.; Chemical Indexing Equivalent to 151:433913 (WO)  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080254029	A1	20081016	US 2008-100715	20080410
AU 2008240279	A1	20081023	AU 2008-240279	20080410
CA 2682730	A1	20081023	CA 2008-2682730	20080410
WO 2008127975	A2	20081023	WO 2008-US59885	20080410
WO 2008127975	A3	20090730		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,

AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  
 AR 66016 A1 20090715 AR 2008-101489 20080410  
 EP 2131834 A2 20091216 EP 2008-745485 20080410  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
 IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,  
 SK, TR  
 KR 2010014565 A 20100210 KR 2009-7019961 20080410  
 JP 2010523695 T 20100715 JP 2010-503203 20080410  
 US 20090182035 A1 20090716 US 2009-406755 20090318  
 WO 2009126682 A2 20091015 WO 2009-US39859 20090408  
 WO 2009126682 A3 20091210  
 W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,  
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,  
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  
 CN 101641094 A 20100203 CN 2008-80009226 20090921  
 MX 2009010946 A 20091029 MX 2009-10946 20091009  
 PRIORITY APPLN. INFO.:  
 US 2007-911176P P 20070411  
 US 2008-100715 A2 20080410  
 WO 2008-US59885 W 20080410  
 US 2009-406755 A 20090318  
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 AB Disclosed are methods of treating allergic conjunctivitis and allergic  
 rhinitis in a subject that involve topically administering to the subject  
 a composition comprising a pharmaceutically effective amount of an H1  
 antagonist  
 and an anti-TNF $\alpha$  compound Thus, topical ophthalmic composition comprised  
 (in wt%): emedastine 0.05, etanercept 5.0, dibasic sodium phosphate or  
 tromethamine 0.01-0.5, sodium chloride 0.1-0.8, mannitol or sucrose 1-5,  
 polysorbate 80 0.01-0.5, NaOH and/or HCl to pH 7  $\pm$  2, polyquad 0-0.005,  
 purified water q.s. 100.  
 INCL 424133100; 514218000; 514450000; 514214020; 514291000; 514263220;  
 424158100; 424145100; 514012000  
 IPCI A61K0039-395 [I,A]; A61K0031-551 [I,A]; A61K0031-335 [I,A]; A61K0031-55  
 [I,A]; A61P0037-08 [I,A]; A61K0038-16 [I,A]; A61K0031-4353 [I,A];  
 A61K0031-52 [I,A]  
 IPCR A61K0039-395 [I,A]; A61K0031-335 [I,A]; A61K0031-4353 [I,A]; A61K0031-52  
 [I,A]; A61K0031-55 [I,A]; A61K0031-551 [I,A]; A61K0038-16 [I,A];  
 A61P0037-08 [I,A]  
 NCL 424/133.100; 424/145.100; 424/158.100; 514/001.100; 514/214.020;  
 514/218.000; 514/263.220; 514/291.000; 514/450.000  
 CC 63-6 (Pharmaceuticals)  
 IT 57-50-1, Sucrose, biological studies 57-55-6, Propylene Glycol,  
 biological studies 69-65-8, Mannitol 77-86-1, Tromethamine 94-13-3,  
 Propyl Paraben 99-76-3, Methyl Paraben 112-92-5, Stearyl Alcohol  
 151-21-3, Sodium Lauryl Sulfate, biological studies 5636-83-9,  
 Dimetindene 7558-79-4, Dibasic Sodium Phosphate 7647-14-5,  
 Sodium Chloride, biological studies 9005-65-6, Polysorbate 80  
 36653-82-4, Cetyl Alcohol 58581-89-8, Azelastine 75345-27-6, Polyquad  
 79516-68-0, Levocabastine 80012-43-7, Epinastine 83881-51-0,  
 Cetirizine 87233-61-2, Emedastine 100643-71-8, Desloratadine



104987-11-3, Tacrolimus 108612-45-9, Mizolastine 113806-05-6,  
 Olopatadine 125602-71-3, Bepotastine 130018-77-8,  
 Levocetirizine 133550-30-8, AG490 170277-31-3, Infliximab  
 185243-69-0, Etanercept 202475-60-3, WHI-P131 205598-06-7, PNU156804  
 211555-04-3, WHIP-154 211555-05-4, WHIP-97 331731-18-1, Adalimumab  
 477600-75-2, CP-690550 911825-19-9 911825-20-2 1070655-77-4  
 1070655-78-5 1070655-79-6 1070894-00-6, PS 608504

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibitor of TNF $\alpha$  plus antihistamine use to treat allergic  
 rhinitis and allergic conjunctivitis)

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:1312374 CAPLUS <<LOGINID::20110605>>

DOCUMENT NUMBER: 146:68699

TITLE: Method and composition comprising polar lipid  
 liposomes for treating inflammatory disorders

INVENTOR(S): Pereswetoff-Morath, Lena; Carlsson, Anders

PATENT ASSIGNEE(S): Biolipox AB, Swed.

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006131737	A2	20061214	WO 2006-GB2090	20060608
WO 2006131737	A3	20070329		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006256518	A1	20061214	AU 2006-256518	20060608
CA 2608631	A1	20061214	CA 2006-2608631	20060608
EP 1888033	A2	20080220	EP 2006-744143	20060608
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, MK, YU			
JP 2008542438	T	20081127	JP 2008-515287	20060608
NO 2007005660	A	20080222	NO 2007-5660	20071107
IN 2007DN08751	A	20071214	IN 2007-DN8751	20071114
KR 2008016621	A	20080221	KR 2007-7028659	20071207
MX 2007015577	A	20080225	MX 2007-15577	20071207
CN 101193622	A	20080604	CN 2006-80020535	20071210
US 20090220583	A1	20090903	US 2009-921850	20090410
PRIORITY APPLN. INFO.:			US 2005-688698P	P 20050609
			US 2005-696777P	P 20050707
			WO 2006-GB2090	W 20060608

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:68699

AB Homogeneous pharmaceutical compns. for the treatment of inflammatory disorders are provided, comprising an anti-inflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically acceptable aqueous carrier. Thus, an injection solution was prepared containing fluticasone propionate 0.5 mg, soybean (Lipoid S100) 17.5 mg, DMPC 17.5 mg, benzalkonium chloride 0.1 mg, butylated hydroxytoluene 0.1 mg, citric acid 19.2 mg, sodium hydroxide 8.4 mg, 1M HCl and/or 1M NaOH to pH 5.5, and water for injection to 1 mL.

IPCI A61K0009-127 [I,A]; A61P0011-02 [I,A]; A61P0011-06 [I,A]; A61P0029-00 [I,A]; A61K0031-55 [I,A]; A61K0031-58 [I,A]; A61K0009-127 [I,C]; A61K0031-381 [I,C]; A61K0031-403 [I,C]; A61K0031-415 [I,C]; A61K0031-55 [I,C]; A61K0031-56 [I,C]; A61K0031-58 [I,C]; A61P0011-00 [I,C]; A61P0029-00 [I,C]; A61K0009-127 [I,A]; A61K0031-381 [I,A]; A61K0031-405 [I,A]; A61K0031-415 [I,A]; A61K0031-55 [I,A]; A61K0031-56 [I,A]; A61K0031-58 [I,A]; A61P0011-02 [I,A]; A61P0011-06 [I,A]; A61P0029-00 [I,A]  
 IPCR A61K0009-127 [I,C]; A61K0009-127 [I,A]; A61K0031-381 [I,C]; A61K0031-381 [I,A]; A61K0031-403 [I,C]; A61K0031-405 [I,A]; A61K0031-415 [I,C]; A61K0031-415 [I,A]; A61K0031-55 [I,C]; A61K0031-55 [I,A]; A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61K0031-58 [I,C]; A61K0031-58 [I,A]; A61P0011-00 [I,C]; A61P0011-02 [I,A]; A61P0011-06 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]

CC 63-6 (Pharmaceuticals)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-81-7, L-Ascorbic acid, biological studies 57-15-8, Chlorobutanol 58-73-1, Diphenhydramine 59-02-9,  $\alpha$ -Tocopherol 59-32-5, Chloropyramine 60-00-4, Ethylenediaminetetraacetic acid, biological studies 60-12-8, Phenylethyl alcohol 60-87-7, Promethazine 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 67-43-6, Diethylenetriaminepentaacetic acid 67-73-2, Fluocinolone acetonide 68-04-2, Sodium citrate 68-88-2, Hydroxyzine 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 82-88-2, Phenindamine 82-92-8, Cyclizine 82-93-9 82-95-1, Buclizine 83-43-2, Methylprednisolone 84-96-8, Alimemazine 86-21-5, Pheniramine 86-22-6 87-69-4, Tartaric acid, biological studies 91-75-8, Antazoline 91-79-2, Thenyldiamine 91-81-6, Tripelennamine 91-84-9, Mepyramine 91-85-0, Thonzylamine 92-12-6, Phenyltoloxamine 94-13-3, Propylparaben 94-26-8, Butylparaben 99-76-3, Methylparaben 110-17-8, Fumaric acid, biological studies 110-44-1, Sorbic acid 118-23-0, Bromazine 120-47-8, Ethylparaben 121-79-9, Propyl gallate 122-99-6, Phenoxyethanol 124-94-7, Triamcinolone 127-09-3, Sodium acetate 128-37-0, Butylated hydroxytoluene, biological studies 129-03-3, Cyproheptadine 132-22-9, Chlorophenamine 134-03-2, Sodium ascorbate 138-56-7, Trimethobenzamide 139-33-3 147-20-6, Diphenylpyraline 152-97-6, Fluocortolone 298-55-5, Clocinazine 298-57-7, Cinnarizine 314-03-4, Pimethixene 356-12-7, Fluocinonide 362-29-8, Propiomazine 378-44-9, Betamethasone 426-13-1, Fluorometholone 442-52-4, Clemizole 469-21-6, Doxylamine 482-15-5, Isothipendyl 486-12-4, Triprolidine 486-16-8, Carbinoxamine 523-87-5, Dimenhydrinate 524-81-2 569-65-3, Meclozine 604-51-3, Deptropine 606-90-6, Piprinhydrinate 688-57-3, Ethylenediaminetriacetic acid 848-53-3, Homochlorocyclizine 1406-18-4, Vitamin E 1420-55-9, Thiethylperazine 1982-37-2, Methdilazine 2193-87-5, Fluprednidene 2644-64-6, Dipalmitoylphosphatidylcholine 3093-35-4, Halcinonide 3565-72-8, Embramine 3689-50-7, Oxomemazine 3964-81-6, Azatadine 4419-39-0, Beclometasone 4945-47-5, Bamipine 5632-44-0, Tolpropamine 5636-83-9, Dimetindene 6915-15-7, Malic acid 7456-24-8, Dimetotiazine 7558-79-4, Disodium phosphate 7558-80-7,

Sodium dihydrogen phosphate 7631-90-5, Sodium bisulfite 7647-14-5, Sodium chloride, biological studies 7664-38-2, Phosphoric acid, biological studies 7681-57-4, Sodium metabisulfite 7757-83-7, Sodium sulfite 7758-11-4, Dipotassium phosphate 7778-77-0, Potassium dihydrogen phosphate 9003-39-8, Povidone 9003-39-8D, Polyvinylpyrrolidone, crosslinked 9004-65-3, Hydroxypropylmethyl cellulose 10447-39-9, Quifenadine 14484-47-0, Deflazacort 14504-73-5, Tritoqualine 15686-51-8, Clemastine 16731-55-8, Potassium metabisulfite 18656-38-7, Dimyristoylphosphatidylcholine 18656-40-1, Dilauroylphosphatidylcholine 25013-16-5, Butylated hydroxyanisole 25122-41-2, Clobetasol 25322-68-3, Polyethylene glycol 25523-97-1, Dexchlorpheniramine 27367-90-4, Niaprazine 29216-28-2, Mequitazine 38098-46-3, Monothioglycerol 49697-38-3, Rimexolone 50679-08-8, Terfenadine 51333-22-3, Budesonide 52468-60-7, Flunarizine 54063-32-0, Clobetasone 58581-89-8, Azelastine 59198-70-8, Diflucortolone valerate 60607-34-3, Oxatomide 61361-72-6, Dimyristoylphosphatidylglycerol 63644-55-3, Dilauroylphosphatidylglycerol 64294-95-7, Setastine 67452-97-5, Alclometasone 68737-67-7, Dioleoylphosphatidylcholine 68844-77-9, Astemizole 79516-68-0, Levocabastine 79794-75-5, Loratidine 80012-43-7, Epinastine 80474-14-2, Fluticasone propionate 83799-24-0, Fexofenadine 87233-61-2, Emedastine 87848-99-5, Acrivastine 90566-53-3, Fluticasone 90729-43-4, Ebastine 100643-71-8, Desloratadine 105102-22-5, Mometasone 108612-45-9, Mizolastine 111406-87-2, Zileuton 113806-05-6, Olopatadine 125602-71-3, Bepotastine 126544-47-6, Ciclesonide 158876-82-5, Rupatadine 158966-92-8, Montelukast 202409-33-4, Etoricoxib 214334-87-9, Dioleoylphosphatidylglycerol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(homogeneous compns. comprising anti-inflammatory and/or antihistaminic agents, polar lipid liposomes and aqueous carrier for treating inflammatory disorders)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:100995 CAPLUS <<LOGINID::20110605>>

DOCUMENT NUMBER: 140:117446

TITLE: Aqueous liquid preparations and light-stabilized aqueous liquid preparations of bepotastine

INVENTOR(S): Higashiyama, Masayo

PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011001	A1	20040205	WO 2003-JP9713	20030730
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,			

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003252746 A1 20040216 AU 2003-252746 20030730  
 JP 3631748 B2 20050323 JP 2004-524320 20030730  
 EP 1525884 A1 20050427 EP 2003-771445 20030730  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 CN 1612734 A 20050504 CN 2003-801903 20030730  
 CN 1293880 C 20070110  
 KR 1016595 B1 20110222 KR 2004-7010338 20030730  
 US 20050107429 A1 20050519 US 2004-500354 20040630  
 PRIORITY APPLN. INFO.: JP 2002-223804 A 20020731  
 WO 2003-JP9713 W 20030730

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed are aqueous liquid prepns. containing  
 (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid  
 or pharmacol. acceptable acid-addition salts thereof, which are stabilized  
 with water-soluble metal chlorides. An eye drop solution contained bepotastine  
 besilate 0.3, NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O 0.1, NaCl 0.79, benzalkonium chloride  
 0.005 g, NaOH q.s. to pH 6.8, and distilled water to 100 mL.  
 IPCI A61K0031-4545 [ICM,7]; A61K0009-08 [ICS,7]; A61K0047-02 [ICS,7];  
 A61P0011-02 [ICS,7]; A61P0017-04 [ICS,7]; A61P0027-02 [ICS,7]; A61P0027-14  
 [ICS,7]; A61P0037-08 [ICS,7]; A61P0043-00 [ICS,7]  
 IPCR A61K0009-08 [I,A]; A61K0009-00 [I,A]; A61K0031-4545 [I,A]; A61K0047-02  
 [I,A]; A61P0011-02 [I,A]; A61P0017-04 [I,A]; A61P0027-02 [I,A];  
 A61P0027-14 [I,A]; A61P0027-16 [I,A]; A61P0037-08 [I,A]; A61P0043-00  
 [I,A]; C07D0401-12 [I,A]  
 CC 63-6 (Pharmaceuticals)  
 IT 7447-40-7, Potassium chloride, biological studies  
 7647-14-5, Sodium chloride, biological studies  
 10043-52-4, Calcium chloride, biological studies  
 125602-71-3, Bepotastine 190786-44-8, Bepotastine besilate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (stabilized aqueous solns. containing bepotastine and metal chlorides)  
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log ha  
 'HA' IS NOT VALID HERE  
 For an explanation, enter "HELP LOGOFF".

=> log h

(FILE 'HOME' ENTERED AT 20:33:21 ON 05 JUN 2011)

FILE 'REGISTRY' ENTERED AT 20:34:10 ON 05 JUN 2011

E BEPOTASTINE/CN  
 L1 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON BEPOTASTINE/CN  
 E SODIUM CHLORIDE/CN  
 L2 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "SODIUM CHLORIDE"/CN  
 E POTASSIUM CHLORIDE/CN  
 L3 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "POTASSIUM CHLORIDE"/  
 CN  
 E CALCIUM CHLORIDE/CN

10/500,354

L4                   1 SEA FILE=REGISTRY SPE=ON   ABB=ON   PLU=ON   "CALCIUM CHLORIDE"/CN

FILE 'CAPLUS' ENTERED AT 20:35:20 ON 05 JUN 2011

L5                   0 SEA FILE=CAPLUS SPE=ON   ABB=ON   PLU=ON   L1 (L) (L2 OR L3 OR  
                    L4)

L6                   43 SEA FILE=CAPLUS SPE=ON   ABB=ON   PLU=ON   L1

FILE 'CAPLUS, BIOSIS, EMBASE, MEDLINE' ENTERED AT 20:37:03 ON 05 JUN 2011

L7                   140 SEA FILE=MFE SPE=ON   ABB=ON   PLU=ON   L1

L8                   0 SEA FILE=MFE SPE=ON   ABB=ON   PLU=ON   L1 (L) (L2 OR L3 OR L4)

L9                   6 SEA FILE=MFE SPE=ON   ABB=ON   PLU=ON   L1 AND (L2 OR L3 OR L4)  
                    D IBIB ABS HITIND 1-6